In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
During the COVID-19 pandemic he was part of the “public face” for media and community groups, conducting over 100 interviews, seminars and media conferences, including with the Prime Minister and Health Minister.
He became synonymous with, and the public face of, the Therapeutic Goods Administration, leaving behind an extraordinary record of public service.
During this time it was his reassurances that left Australians confident in the approval and regulation of medicines, vaccines and treatments.
“Professor Skerritt has had many achievements over the course of his career including Implementing the Medicines and Medical Devices Review, digital transformation, the regulation of medicinal cannabis, the rapid registration of COVID vaccines and treatments and playing a leading role in international harmonisation of regulation.”, said The Hon Mark Butler MP, Minister for Health and Aged Care in a press release issued in February the same year.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
About ARCS and its transformation in 2023
ARCS Australia is the association for people working on the development of therapeutics. The ARCS conference brings over 1500 people across the sector, in Australia, with international speakers coming this year. The conference runs over 3 days with 7 concurrent streams that cover all the areas that are involved in the development of therapeutics, including clinical research, regulatory affairs and pharmacovigilance.
The focus for ARCS at this year’s conference has been building competency frameworks in the areas that members work. As a significant step, ARCS is transforming into a professional body that both recognises and develops people into specific competencies that are required for the roles that those people are undertaking.
Dr Shanny Dyer states, “One of the key goals that ARCS is undertaking over this strategic period is to implement the professionalisation of our sector. Whilst we’ve been very clearly developing products that have safety, quality and efficacy, we now need to work on the quality of our staff, their ability to develop products and have a safe pair of hands and to work efficiently as well.”
-
Pharmacy led men’s urological health
Men’s urological needs refer to the medical and surgical conditions that affect the male urinary tract system and reproductive organs.
A urologist can address these concerns, however a pharmacy-led model of care developed by Brad Butt, called Mens Health Downunder has offered an alternative to certain urological needs of the male adult population over the past 10 years.
Australian Health Journal met with Brad to hear about his journey, Mens Health Downunder and the impact the pharmacy-led model of care has had on patient’s urological as well as mental health.
-
Health Minister appoints Chair to National One Stop Shop Program
The Australian Government has appointed Emeritus Professor Ian Chubb AC, FAA FTSE to lead key reforms as Chair of the Inter-Governmental Policy Reform Group (IGPRG) for health and medical research, including clinical trials.
Minister for Health and Aged Care, The Hon Mark Butler MP on the selection and appointment said, “Professor Chubb has dedicated his career to improving health and medical research and education in this county and I am pleased he has agreed to share his knowledge and experience through the IGPRG.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
